Serum visfatin in chronic renal failure patients on maintenance hemodialysis: a correlation study

Abstract

Background and aim of work Endothelial dysfunction, atherosclerosis, and cardiovascular disease are strongly linked to chronic kidney disease. It has been hypothesized that visfatin may play an important role in uremia-related atherosclerosis and the relation between visfatin and endothelial dysfunction has been proved. We aimed to study and characterize the relation of visfatin to some clinical and biochemical parameters among chronic renal failure (CRF) patients on regular hemodialysis. Patients and methods This study was carried out on a total of 90 individuals, divided into two groups: group A included 68 patients with CRF on regular hemodialysis (44 men and 24 women) and group B included 22 healthy individuals as controls (four men and 18 women). All participants were subjected to the following: full clinical assessment, BMI assessment, FBS (Fasting blood sugar), PPBS (postprandial blood sugar), Hb level, lipid profile, serum urea, creatinine, potassium, phosphorus, and serum visfatin. Results Serum visfatin concentration was significantly high in group A (uremic on hemodialysis) compared with group B (control) (48.95 ng/ml ±11.62 compared with 22.65 ng/ml ± 5.24; P < 0.001); a highly significant positive correlation was found between serum visfatin and serum low-density lipoprotein (r = 0.39; P < 0.001) and a significant positive correlation between serum visfatin and serum triglycerides and serum uric acid (r = 0.28; P < 0.05 and r = −0.24; P < 0.05), respectively, whereas a highly significant negative correlation between serum visfatin and Hb (r = −0.43; P < 0.001) and a significant negative correlation between serum visfatin and serum urea (r = −0.25; P < 0.05), blood sugar, both fasting and postprandial (r = −0.34; P < 0.001 and r = −0.39; P < 0.001), respectively, were found in the patients in group A, without a significant correlation either to high-density lipoprotein, serum creatinine, the etiology of CRF, or to the duration of dialysis in the patients in group A. Conclusion This study proves the association of serum visfatin with CRF, unrelated to the biochemical parameter of kidney functions; however, further studies to examine visfatin expression within renal tissue may clarify its definitive role in CRF.

Visfatin versus Flow-Mediated Dilatation as a Marker of Endothelial Dysfunction in Pediatric Renal Transplant Recipients

“…HD patients had significantly higher level; with more than 10 folds of normal controls. This in agree with the study was done on 68 patients on HD patients compared with 22 healthy controls, showed a highly significant increase in serum visfatin in the CKD group on HD in comparison with the healthy control participants [ 15 ].…”

“…Among laboratory data obtained, significant correlations were found mainly between serum triglycerides and visfatin serum level (r = 0.49, p = 0.0006). The similar positive correlation was found by others [ 7 , 15 ].…”

ssociation between serum visfatin and carotid atherosclerosis in diabetic and non-diabetic patients on maintenance hemodialysis

“…In our study, we demonstrated a statistically significant difference in serum TG, LDLc, and HDLc levels in the HD group compared to the control group. Previous studies ( 21 , 15 ) had similar results, showing that higher visfatin levels were associated with decreased GFR, increased serum triglyceride and LDL cholesterol levels, and impaired endothelial function. Therefore, one would expect an increased probability of cardiovascular events in CKD patients with elevated serum visfatin concentrations due to their increased levels of TG and their reduced level of HDL cholesterol ( 21 ).…”

“…This was in agreement with Mu et al who supported, at least in part, the role of visfatin in uremia-related atherosclerosis ( 21 ). However, Lotfy et al showed no significant correlation between serum visfatin and HDLc ( 15 ). IMT showed a statistically significant difference between HD and control group (p < 0.01), suggesting that visfatin may reflect the degree of atherosclerosis in the carotid vascular bed of HD patients.…”

“…Serum visfatin concentration was significantly higher in uremic patients on hemodialysis compared with the control; serum visfatin is upregulated in these patients. However, further investigations of the relationship between serum visfatin and the various pathophysiological aspects of renal disease are warranted ( 15 ). Elevated visfatin related to markers of inflammation might represent a novel link between inflammation and adipocytokines in dialyzed patients.…”